4-(3-Phenylimidazo[4,5-b]pyridin-6-yl)phenol | 221636-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(3-Phenylimidazo[4,5-b]pyridin-6-yl)phenol
• CAS: 221636-13-1
• 化学式: C₁₈H₁₃N₃O
• 分子量: 287.321
• InChiKey: DLIWVNLYUAZXJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-氯乙基)哌啶 、 4-(3-Phenylimidazo[4,5-b]pyridin-6-yl)phenol 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-phenyl-6-(4-(2-(1-piperidinyl)ethoxy)phenyl)imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

  摘要：

  1, 5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00485-2
• 作为产物：
  描述：

  5-溴-2-氯-3-硝基吡啶 在 N-甲基吡咯烷酮 、 四(三苯基膦)钯 、 氢溴酸 、 sodium carbonate 、 溶剂黄146 、 锌 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(3-Phenylimidazo[4,5-b]pyridin-6-yl)phenol
  参考文献：
  名称：

  Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

  摘要：

  1, 5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00485-2

文献信息

• Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR
  作者：Mark T. Bilodeau、April M. Cunningham、Timothy J. Koester、Patrice A. Ciecko、Kathleen E. Coll、William R. Huckle、Randall W. Hungate、Richard L. Kendall、Rosemary C. McFall、Xianzhi Mao、Ruth Z. Rutledge、Kenneth A. Thomas

  DOI：10.1016/s0960-894x(03)00485-2

  日期：2003.8

  1, 5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.